Sleep and wakefulness are controlled by a wide range of neuronal populations in the mammalian brain. Activation of adenosine A 2A receptor (A 2A R)-expressing neurons in the nucleus accumbens (NAc) core promotes slow-wave sleep (SWS). The neuronal mechanism by which activation of NAc A 2A R neurons induces SWS, however, is unknown. We hypothesized that the ability of NAc activation to induce sleep is mediated by the classic somnogen adenosine, which can be formed by various processes in all types of cells. Here, to investigate whether astrocytes are involved in the ability of the NAc to regulate SWS, we ablated glial fibrillary acidic protein (GFAP)-positive cells in the NAc core of mice by virus-mediated expression of diphtheria toxin (DT) receptors and intraperitoneal administration of DT. Analysis of electroencephalogram and electromyogram recordings of DT-treated wild-type mice revealed that SWS was remarkably increased at 1 week after DT treatment, whereas sleep-wake behavior was unchanged in DT-treated A 2A R knockout mice. Cell ablation was associated with an increased number of GFAP-positive cells and activation of microglia in the NAc. In-vivo microdialysis revealed significantly increased levels of extracellular adenosine in the NAc at 1 week after DT treatment. Our findings suggest that elevated adenosine levels in the NAc core promote SWS by acting on A 2A Rs and provide the first evidence that adenosine is an endogenous candidate for activating NAc A 2A R neurons that have the ability to induce SWS.
Introduction
Sleep is a common phenomenon in organisms ranging from simple worms to human beings, but is still poorly understood. Adenosine A 2A receptor (A 2A R)-expressing neurons in the nucleus accumbens (NAc) play a prominent role in sleep control mediated by motivated behavior (Oishi et al., 2017) . Adenosine is an obvious candidate molecule that activates NAc A 2A R-expressing neurons because sufficient levels of adenosine, a well-described endogenous somnogen (Porkka-Heiskanen et al., 1997) , are available under basal conditions and excitatory A 2A Rs are abundantly expressed in the indirect pathway of the NAc (Rosin et al., 1998) . The source of the adenosine, however, remains obscure.
In principle, adenosine (and ATP, which is rapidly degraded into adenosine) can be released in the brain from neurons and glia cells. Genetically engineered mice in which a dominant negative soluble Nethylmaleimide-sensitive factor attachment protein receptor (dnSNARE) domain is selectively expressed in astrocytes to nonspecifically block the release of ATP exhibit decreased levels of extracellular adenosine and recovery sleep after sleep deprivation (Chen and Scheller, 2001; Halassa et al., 2009; Pascual et al., 2005; Raingo et al., 2012) , suggesting that adenosine released from astrocytes is involved in the accumulation of sleep pressure. Moreover, adenosinergic regulation of the homeostatic sleep need via activation of neuronal adenosine A 1 receptors is controlled by glial adenosine kinase (Bjorness et al., 2016) . These findings implicate astrocytes as a promising source of adenosine in sleep regulation; however, the role of NAc astrocytes in sleep regulation is not known.
In this study, we ablated some glial fibrillary acidic protein (GFAP)-positive cells, likely astrocytes, and a small number of neurons in the NAc of mice using virus-mediated expression of diphtheria toxin (DT) receptors (DTR) and intraperitoneal (i.p.) administration of DT. Extracellular adenosine and slow-wave sleep (SWS) were both increased in A 2A R wild-type mice, but SWS was not increased in A 2A R knockout mice. Surprisingly, the ablation led to an increased number of https://doi.org/10.1016/j.neuint.2019.01.020 Received 29 October 2018; Received in revised form 7 January 2019; Accepted 19 January 2019 GFAP-positive cells and activated microglia in the NAc.
Materials & methods

Animals
A mouse strain expressing enhanced yellow fluorescent protein (EYFP) in mouse GFAP-positive cells (lox-stop-lox-EYFP/mGFAP-Cre) was established by crossing R26-stop-EYFP mice (Jackson Laboratory, strain number 007903) (Srinivas et al., 2001 ) with mGFAP-Cre mice (Garcia et al., 2004) . In addition, a global A 2A R knockout mouse line was used (Chen et al., 1999) . All mice (weighing 20-35 g, 8-24 weeks old) used in the present study were housed at a constant temperature of 23 ± 1°C with a relative humidity of 60 ± 2% on an automatically controlled 12-h light/dark cycle (lights on at 7:00, off at 19:00), and provided water and food ad libitum. All experiments were performed in accordance with the Animal Care Committee of the University of Tsukuba and the National Institutes of Health Guide for the Care and Use of Laboratory Animals, and every effort was made to minimize the number of animals used, as well as any pain and discomfort.
Plasmids and adeno-associated virus (AAV) generation
To generate the pAAV-GFAP-DTR-P2A-mCherry plasmid, the hM4D (Gi) fragment in pAAV-GFAP-hM4D(Gi)-mCherry, kindly provided by Dr. Bryan Roth (University of North Carolina; Addgene plasmid #50479), was replaced with a polymerase chain reaction (PCR)-amplified fragment containing the DTR-P2A coding sequence using restriction cloning.
The AAV serotypes of shH10 for recombinant AAV-GFAP-DTRmCherry and AAV-GFAP-mCherry were generated as described previously (Zolotukhin et al., 1999) . In brief, the AAVs were generated by tripartite transfection into 293A cells. After 3 days, the 293A cells were resuspended in artificial cerebrospinal fluid, freeze-thawed four times, and treated with Benzonase ® nuclease (Millipore, Burlington, MA) to degrade all forms of DNA and RNA. Subsequently, the cell debris was removed by centrifugation and the virus titer in the supernatant was determined using an AAVpro Titration Kit for Real Time PCR (Takara Bio, Kusatsu, Japan).
Stereotaxic AAV injection, electroencephalogram (EEG)/ electromyogram (EMG) recordings and vigilance state assessment
Surgeries for brain microinjections were conducted under pentobarbital anesthesia (60 mg/kg, i.p.). Using aseptic techniques, the mice were stereotaxically and bilaterally injected into the NAc with recombinant AAV-GFAP-DTR-mCherry (264 nl/side, 1 × 10 11 particles ml −1
) or AAV-GFAP-mCherry (264 nl/side, 9 × 10 10 particles ml −1 ) with a glass micropipette and an air pressure injector system (Chamberlin et al., 1998) . The following coordinates were used according to the mouse brain atlas of Paxinos and Franklin (2001) : AP + 1.5 mm; ML ± 1.2 mm; DV -4.1 mm.
Mice were chronically implanted with EEG and EMG electrodes for polysomnography, as previously described (Oishi et al., 2016) . Briefly, the implant contained two stainless-steel screws (1 mm diameter) serving as EEG electrodes, one of which was placed epidurally over the right frontal cortex (1.0 mm anterior and 1.5 mm lateral to bregma) and the other over the right parietal cortex (1.0 mm anterior and 1.5 mm lateral to lambda). Two insulated Teflon-coated, silver wires (0.2 mm in diameter), which were placed bilaterally into the trapezius muscles, served as EMG electrodes. Both EEG and EMG electrodes were connected to a microconnector, and the whole assembly was then fixed to the skull with self-curing dental acrylic resin.
After recovering for at least 3 weeks, the mice were connected to an EEG/EMG recording cable in a soundproof recording chamber and habituated for at least 3 days before any polysomnographic recording.
The EEG/EMG signals were amplified, filtered (EEG, EMG, , digitized at a sampling rate of 128 Hz, and recorded using SLEEPSIGN software ver. 3 (Kissei Comtec, Matsumoto, Japan) (Kohtoh et al., 2008) .
EEG/EMG data visualized by the analysis software were calculated in 10-s epochs and three stages were recognized based on their spectrum and wave properties (Oishi et al., 2016) : SWS, rapid eye movement (REM) sleep, and wakefulness. Percent change of slow-wave activity (SWA) was calculated based on the SWS delta power (0.5-4 Hz) during 24 h and normalized to the baseline condition.
2.4. Microdialysis in freely behaving mice and measurement of adenosine by high-performance liquid chromatography (HPLC)
Under pentobarbital anesthesia (60 mg/kg, i.p.), mice were bilaterally implanted with guide cannulas (inner diameter 0.40 mm, outer diameter 0.50 mm; Eicom, Kyoto, Japan) into the brain using the following coordinates according to the mouse brain atlas of Paxinos and Franklin (2001) : AP +1.4 mm; ML ± 1.2 mm; DV −2.9 mm. Two stainless-steel screws (1 mm diameter) were also implanted to stabilize the guide cannulas, and then dummy cannulas (diameter 0.37 mm, Eicom) were inserted to prevent the guide cannula from clogging. After recovering for at least 3 weeks, the mice were transferred to the recording chambers for habituation. On the sampling day, each mouse was quickly anesthetized using isoflurane and the dummy cannula was removed followed by insertion of the microdialysis probe (1 mm membrane length, 8.4% adenosine recovery rate; Eicom) into the guide cannula. The probe was infused continuously using an infusion pump with Ringer's solution (147 mM NaCl, 4 mM KCl, and 2.4 mM CaCl 2 ) at a flow rate of 0.5 μl/min. Two hours after inserting the probe, dialysates were continuously collected from the probe for 3 h. The dialysates were kept at −20°C until adenosine was measured by HPLC. A TSKgel ® ODS-100V HPLC column (Tosoh Bioscience, Tokyo, Japan) together with a mobile phase comprising 100 mM NaH 2 PO 4 and acetonitrile in a ratio of 96:4 at a flow rate of 1 ml/min was used for HPLC separation, and 80 μl of each dialysate was injected into a HPLC-LabSolutions LC system (Shimadzu, Kyoto, Japan) equipped with a UV (260 nm) detection system. External adenosine standards were used to determine the retention time and to calculate the adenosine concentrations in the dialysates by the HPLC software.
Histology
Under deep chloral hydrate (500 mg/kg, i.p.) anesthesia, the mice were perfused via the heart with saline followed by a 10% formalin solution. The brains were removed and immersed in the same fixative overnight at 4°C and then transferred into a 20% sucrose solution.
For immunohistochemistry, the brains were then frozen on dry ice and sectioned at 40 μm on a freezing microtome (Thermo Fisher Scientific, Waltham, MA). Immunohistochemistry was performed on free-floating sections as described previously (Lazarus et al., 2011) . In brief, the sections were rinsed in PBS, incubated in 0.3% hydrogen peroxide in PBS for 30 min at room temperature, and then sequentially incubated at room temperature in 3% normal donkey serum and 0.25% Triton X-100 in PBS (PBT) for 1 h and then overnight in primary antibody diluted in PBT with 0.02% sodium azide. After overnight incubation with rabbit anti-DsRed antibody (1:5000; Cat# 632496, Takara Bio), the sections were rinsed and incubated for 2 h in biotinylated antibody (Jackson ImmunoResearch Lab, West Grove, PA) at a dilution of 1:1000. All tissue sections were then treated with avidin-biotin complex (1:1000; Vectastain ABC Elite kit, Vector Labs, Burlingame, CA) for 1 h, and immunoreactive cells were visualized by reaction with 3,3′-diaminobenzidine and 0.01% hydrogen peroxide. Tissue sections mounted on glass slides were scanned with a Hamamatsu NanoZoomer-XR Digital slide scanner (Hamamatsu Photonics, Hamamatsu, Japan), and digital photomicrographs were analyzed using Hamamatsu NDPView software v2.4.26.
For fluorescent double-labeling, the sections were rinsed in PBT and incubated in PBT containing 10% BlockAce (DS PharmaBiomedical, Osaka, Japan) for 30 min at room temperature. The sections were then incubated with the rabbit anti-GFAP antibody (1:200, Cat# HPA056030, Sigma-Aldrich, St. Louis, MO), goat anti-mCherry antibody (1:1000, Cat# AB0040-200, SICGEN, Cantanhede, Portugal), mouse anti-NeuN antibody (1:100, Cat# MAB377, Millipore), rabbit anti-S100β (1:100, Cat# HPA015768, Sigma-Aldrich, St. Louis, MO) or rabbit anti-TMEM119 antibody (1:200, Cat# ab209064, Abcam, Cambridge, UK) containing 5% BlockAce at room temperature in the combinations described in the Results section. After overnight incubation, the sections were rinsed in PBT and incubated with donkey antigoat Alexa Fluor ® 594 nm (1:1000, Thermo Fisher Scientific), donkey anti-mouse Alexa Fluor ® 647 nm (1:500, Thermo Fisher Scientific), or donkey anti-rabbit Alexa Fluor ® 647 nm (1:500, Thermo Fisher Scientific) containing 5% BlockAce for at least 2 h. The sections were then mounted on glass slides and sealed with mounting medium containing DAPI dye (Vector Labs, Cat# H-1200) and cover glass. Fluorescence signals were visualized using an LSM 700 confocal microscope (Zeiss, Oberkochen, Germany). For quantitative histologic analysis, pictures of tissues containing the NAc at the same bregma level were obtained using a confocal microscope in the Z stack mode. In Fig. 1b , a 0.35 mm × 0.35 mm area in the NAc of each tissue was analyzed. The percentage of NeuN/mCherry and S100β/mCherry-positive cells among mCherry/DAPI-positive cells was calculated. In Fig. 3g , the number of GFAP/DAPI-positive cells was counted in and normalized to the AAV area. The AAV area (i.e., the area showing mCherry expression) was measured using ImageJ software.
Statistical analysis
Data are presented as mean ± standard error of the mean (SEM) and were analyzed using SPSS statistics 25 (IBM, Armonk, NY). Oneway analysis of variances (ANOVA) followed by the Fisher's Protected Least Significant Difference (PLSD) test or two-way ANOVA followed by the PLSD test was performed for all the statistical analysis. In all cases, a p-value less than 0.05 was considered significant.
Results
SWS increased after cytotoxic ablation of NAc GFAP-positive cells
To examine the role of NAc astrocytes in sleep-wake regulation, we ablated GFAP-positive cells in the NAc core of mice by stereotaxic microinjection of AAV carrying DTR under a GFAP promoter (AAV-GFAP-DTR, Fig. 1a ) and i.p. injection of DT (Wako, Japan) 3 weeks after microinjection (Saito et al., 2001 ). AAV-GFAP-DTR was injected in loxstop-lox-EYFP/mGFAP-Cre mice, denoted as A 2A R WT mice, or A 2A R knockout mice (A 2A R KO mice).
First, we evaluated the specificity of DTR expression in AAV-GFAP-DTR-injected A 2A R WT mice by immunohistochemical investigation of the expression of the neuronal marker NeuN, the astrocytic marker S100β and the AAV-reporter protein mCherry (Fig. 1b) Fig. 2a and b) .
Three weeks after the AAV injections, EEG and EMG recordings of the mice were analyzed to assess the baseline sleep/wake behavior of the animals. Initially, only A 2A R WT NAc GFAP-DTR mice were treated with DT (50 μg/kg, i.p.), and EEG and EMG recordings were obtained on days 9-14 following the treatment. We analyzed SWS amounts in A 2A R WT NAc GFAP-DTR mice during dark and light periods compared with the baseline. We found that SWS was significantly increased in the dark and light periods of day 9 and then gradually returned to the baseline level until day 14 (Fig. 2c) . Therefore, we next obtained EEG Abbreviations used: aca, anterior commissure; CPu, caudate putamen. Scale bar: 200 μm c SWS during the dark and light periods 1 day before and at 9-14 days after DT treatment in A 2A R WT NAc GFAP-DTR mice (n = 4). **p < 0.01 vs baseline day (i.e., day before DT treatment), assessed by one-way ANOVA. d SWS during the dark and light periods 1 day before and for 9 days after DT treatment in A 2A R WT NAc GFAP-mCherry (n = 5) and NAc GFAP-DTR (n = 6) mice. *p < 0.05, **p < 0.01 vs A 2A R WT NAc GFAP-mCherry mice; assessed by one-way ANOVA. e SWS during the dark and light periods 1 day before and at 1-9 days after DT treatment in A 2A R KO NAc GFAP-mCherry (n = 4) and NAc GFAP-DTR (n = 6) mice. f-i SWS (f, h), and REM-sleep (g, i) time-courses of all the mouse groups on day 7 after DT treatment. *p < 0.05, **p < 0.01 vs A 2A R WT NAc GFAP-mCherry (f, g) or A 2A R KO NAc GFAP-mCherry (h, i) mice; assessed by two-way ANOVA followed by the PLSD test. j, k Mean duration (j) and number (k) of SWS episodes during the dark and light periods on day 7 after DT treatment in A 2A R WT NAc GFAP-mCherry (n = 5) and A 2A R WT NAc GFAP-DTR (n = 6) mice. *p < 0.05 vs A 2A R WT NAc GFAP-mCherry mice, assessed by one-way ANOVA. l, m SWS-SWA time-courses of all the mouse groups on day 7 after DT treatment. * p < 0.05, ** p < 0.01 vs A 2A R KO NAc GFAP-mCherry mice; assessed by two-way ANOVA followed by the PLSD test.
and EMG recordings of A 2A R WT NAc GFAP-DTR and NAc GFAPmCherry mice for 9 days after DT treatment. SWS increased in the A 2A R WT NAc GFAP-DTR mice during the dark period from day 5 after DT treatment before reaching a maximum on day 7 after DT treatment, compared with DT-treated control mice (day 5: F (1, 9) = 7.808, p = 0.011; day 6: F (1, 9) = 6.470, p = 0.024; day 7: F (1, 9) = 21.858, p = 0.0001; day 8: F (1, 9) = 6.907, p = 0.026; day 9: F (1, 9) = 8.050, p = 0.023; Fig. 2d ). SWS also increased significantly in the A 2A R WT NAc GFAP-DTR mice during the light period between days 1 and 8, compared to the DT-treated control mice (day 1: F (1, 9) = 3.948, p = 0.015; day 2: F (1, 9) = 7.591, p = 0.002; day 3: F (1, 9) = 3.205, p = 0.024; day 4: F (1, 9) = 2.971, p = 0.031; day 5: F (1, 9) = 4.316, p = 0.012; day 6: F (1, 9) = 4.379, p = 0.021; day 7: F (1, 9) = 8.384, p = 0.011; day 8: F (1, 9) = 6.679, p = 0.013; Fig. 2d ). We also stereotaxically microinjected AAV-GFAP-DTR bilaterally into the (Fig. 2e) . This observation suggests that the SWS increase after DT treatment is mediated by adenosine via A 2A R. On day 7, when the mice had the strongest SWS increase, A 2A R WT NAc GFAP-DTR mice exhibited increased SWS and REM sleep, especially during the dark period, compared with DT-treated control mice ( Fig. 2f and g ). Concomitantly, A 2A R WT NAc GFAP-DTR mice had a lower amount of wakefulness (data not shown). By contrast, we did not observe notable changes in the hourly SWS and REM sleep amounts of A 2A R KO NAc GFAP-DTR mice on day 7 after DT treatment, compared with A 2A R KO NAc GFAP-mCherry mice ( Fig. 2h and i) . The increased amount of SWS in A 2A R WT NAc GFAP-DTR mice during the dark period of day 7 after DT treatment was due to an increased number of SWS episodes, while the mean duration of SWS episodes was not changed ( Fig. 2j and k) . A change in SWA is considered a hallmark of sleep homeostasis disturbance (Dispersyn et al., 2017; Wang et al., 2018) . To investigate whether sleep homeostasis was affected by cytotoxic ablation of NAc GFAP-positive cells, we calculated changes in SWA on day 7 normalized to the baseline; however, there was no significant difference in the normalized SWA in all the mouse groups (Fig. 2l, m) .
Cytotoxic ablation of NAc GFAP-positive cells led to increased activation of astrocytes and microglia
We then evaluated the effects of cytotoxic ablation of GFAP-positive cells in the NAc after DT treatment by immunohistochemical investigation of the expression of the astrocyte-reporter protein EYFP and the AAV-reporter protein mCherry (Fig. 3a-c) . No EYFP-and mCherrypositive cells were observed in A 2A R WT NAc GFAP-DTR mice after DT treatment (Fig. 3a) , whereas many double-positive cells were observed in A 2A R WT NAc GFAP-DTR mice treated with saline or A 2A R WT NAc GFAP-mCherry mice treated with DT ( Fig. 3b and c) . These findings suggest that cells infected with AAV-GFAP-DTR were completely ablated by the administration of DT. Next, we examined the residual NAc astrocytes on day 7 after DT administration by immunohistochemical investigation of the expression of the endogenous astrocyte marker GFAP and the AAV-reporter protein mCherry (Fig. 3d-f) . Surprisingly, GFAP expression was remarkably increased in Fig. 3g ).
Because we observed an unexpected increase in GFAP expression after cytotoxic ablation of NAc GFAP-positive cells, we also examined the morphology of microglia in A 2A R WT NAc GFAP-DTR mice by immunohistochemical analysis with an antibody against the microglia marker TMEM119 (Fig. 3h and i) . Activated microglia were detected in DT-treated A 2A R WT NAc GFAP-DTR mice (Fig. 3i) , but not in DT-treated A 2A R WT NAc GFAP-mCherry mice. This observation suggests DT-mediated apoptosis of GFAP cells in the NAc is accompanied by microglia activation.
Extracellular adenosine levels increased after ablation of NAc GFAPpositive cells
Finally, we investigated extracellular adenosine levels on day 7 after DT treatment using microdialysis (Fig. 4a and b) . The dialysates were collected between 19:00 and 22:00 when there is a large increase in SWS and analyzed by HPLC. Dialysates were collected before and after DT treatment by inserting the same probe in contralateral sites of the mouse brain. The adenosine concentration was determined by comparison with adenosine standards (Fig. 4c) and normalized between the samples taken before and after DT treatment due to the varying recovery rates of the microdialysis probes. The position of the microdialysis probe was confirmed by immunohistochemical analysis of the expression of the AAV reporter protein mCherry (Fig. 4d) .
Adenosine levels increased significantly after DT administration in A 2A R WT Fig. 4e ). These findings suggest that ablation of GFAP-positive cells in the NAc results in an increase in extracellular adenosine, at least on day 7 after cell apoptosis is initiated by DT treatment.
Discussion
A recent study showed that chemogenetic or optogenetic activation of NAc core A 2A R neurons projecting to the ventral pallidum strongly induces SWS, whereas chemogenetic inhibition of these neurons prevents sleep induction, but does not affect the homoeostatic sleep rebound (Oishi et al., 2017) . We hypothesized that adenosine is a candidate molecule for activating NAc A 2A R neurons. Where in the NAc adenosine is generated, however, remains unknown. Adenosine is not a neurotransmitter or a typical neuromodulator released from neurons, because it can be formed by various processes in all cell types (Ohana et al., 2001) . Cytotoxic ablation of GFAP-positive cells, which are likely astrocytes, as well as a small number of neurons in the NAc led to a transient increase in SWS over several days in mice. Further analysis of the molecular mechanisms revealed that extracellular adenosine levels increased after ablation and the SWS increase was mediated by A 2A R.
Surprisingly, the number of astrocytes in the NAc core was also increased after GFAP-positive cell ablation. The increase in the number of astrocytes may be due to astrogliosis, i.e., astrocyte migration or proliferation, after apoptotic destruction of astrocytes or neurons by DT (Aldskogius and Kozlova, 1998; Morimoto and Bonavida, 1992) . We suspect that the increase in extracellular adenosine is due to the increased number of astrocytes. A role for astrocytes in sleep regulation has only recently started to emerge. Extracellular levels of adenosine and recovery sleep after sleep deprivation are reduced when the release of ATP is blocked by the transgenic expression of the dnSNARE protein in astrocytes (Chen and Scheller, 2001; Halassa et al., 2009; Pascual et al., 2005; Raingo et al., 2012) and astrocytic adenosine kinase is involved in regulating homeostatic sleep (Bjorness et al., 2016) . Moreover, optogenetic stimulation of astrocytes in the posterior hypothalamus increases sleep (Pelluru et al., 2016) .
The possibility that activated microglia also contribute to the elevated adenosine levels cannot be excluded. Microglia are immune cells distributed throughout the brain, comprising 10%-20% of the glial population (Ginhoux et al., 2013) . Microglia in a phagocytic state are usually involved in the clearance of apoptotic cells (Lian et al., 2016) . The role of microglia in sleep regulation remains elusive. Some studies reported that microglia are activated after sleep deprivation (Huang et al., 2014; Wadhwa et al., 2018; Wisor et al., 2011) . Microglia activation is likely a consequence of sleep loss, however, rather than the cause of sleep rebound. Microglia are considered to be a major source of cytokines, but there is almost no evidence indicating that microglia can release adenosine (Hanisch, 2002; Smith et al., 2012) . In contrast, adenosine has an important role in regulating microglia via adenosine receptors (Gyoneva et al., 2009; Luongo et al., 2014; Madeira et al., 2018; Orr et al., 2009) . Future studies utilizing opto-or chemogenetic systems are needed to examine the ability of microglia to release adenosine and induce sleep. Moreover, cytokines have a known role in sleep/wake regulation, but the effects of cytokines released from microglia in the NAc on sleep have never been investigated. The A 2A R KO NAc GFAP-DTR mice exhibited no increase in SWS after DTR-mediated ablation of astrocytes and neurons, suggesting that cytokines are not involved in the sleep phenotype. Moreover, the DTR was also expressed in neurons to some extent due to leakage of the GFAP promoter used in our viral vector and thus, it is possible that we also ablated a small number of neurons by DT administration. We do not consider this directly relevant, however, because the sleep/wake behavior of A 2A R KO mice is not affected by DTR-mediated ablation of astrocytes and neurons, and cytotoxic lesions of the NAc core or shell neurons induce wakefulness (Qiu et al., 2012) . Neuronal ablation, however, may contribute to activate the astrocytes and microglia (Aldskogius and Kozlova, 1998) . Cytotoxic ablation of astrocytes and neurons may mimic traumatic brain injury (TBI) which is often associated with sleep disorders. TBI patients experience high rates of insomnia (29%), hypersomnia (28%), and sleep apnea (25%) (Wickwire et al., 2016) . For example, hypersomnia was observed in patients with thalamic astrogliosis and increased adenosine levels in the cerebral spinal fluid during an acute period after TBI (Hazra et al., 2014; Rowe et al., 2014; Zuzuárregui et al., 2018 ). An imbalance of neurotransmitters (e.g., GABA, glutamate and orexin) or increased cytokine production in the hypothalamus or brain stem after TBI, however, is believed to cause the sleep disturbance (Sandsmark et al., 2017) . Although adenosine is known to play an important role in neuroprotection after TBI (Lusardi, 2009) , the involvement of adenosine, especially in the NAc, in TBI-related sleep disorders remains unclear.
Conclusion
Activation of A 2A R neurons in the NAc core promotes SWS sleep and elevated adenosine levels in the NAc core increase SWS by acting on A 2A R. Our findings provide the first evidence that adenosine is a strong candidate molecule for activating NAc core A 2A R neurons to induce SWS.
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